FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, pharmacy and pharmacology. What is presented is using 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide (Hypertril) as an active base of drug preparations for correcting dysfunctions of the nitroxydergic system of target organs accompanying homocysteinemia and acute cerebrovascular disorders.
EFFECT: what has been shown is achieving the declared application that is normalising the nitroxydergic function irrespective of whether the NO deficiency or hyperproduction is observed; Hypertril is three times more effective to reduce the homocystein production in comparison to the similar known preparation L-arginine, and has no side effect.
2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR DRUG-INDUCED CORRECTION OF NITROXYDERGIC DISORDERS | 2012 |
|
RU2505297C1 |
| LYSINIUM 3-METHYL-1,2,4-TRIASOLYL-5-THIOACETATE WITH NEUROPROTECTIVE, NOOTROPIC, CARDIOPROTECTIVE, ENDOTHELIOTROPIC, ANTI-ISCHEMIC, ANTIOXIDANT, ANTI-INFLAMMATORY AND ANTIHYPOXIC EFFECT AND LOW TOXICITY | 2007 |
|
RU2370492C2 |
| AGENT POSSESSING ENDOTHELIUM PROTECTIVE EFFECT IN CONDITIONS OF EXPERIMENTAL DIABETES MELLITUS AND CEREBRAL BLOOD CIRCULATION DISORDER | 2015 |
|
RU2601622C1 |
| NEUROTROPIC DRUG AND METHOD OF TREATING STRUCTURAL DISEASES OF NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHIES OF VARIOUS ORIGINS | 2011 |
|
RU2536234C2 |
| CATIONIC ETHER OF L-NITROARGININE CATIONIC TYPE AS INHIBITOR OF MITOCHONDRIAL SYNTHASE OF NITROGEN OXIDE | 2015 |
|
RU2600159C1 |
| APPLICATION OF PTERIDINE DERIVATIVES FOR TREATMENT OF HIGH INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA AND DISEASES ASSOCIATED WITH HIGHER CONTENT OF CYTOTOXIC AND REACTIVE OXYGEN COMPOUNDS | 2003 |
|
RU2348410C2 |
| CATIONIC TETRAPEPTIDE Phe-D-Arg-Phe-Lys-NH AS MITOCHONDRIAL NITROGEN OXIDE SYNTHASE INHIBITOR | 2015 |
|
RU2587062C1 |
| eNOS MUTATIONS USED FOR GENETIC THERAPY AND THERAPEUTIC SCREENING | 2000 |
|
RU2257226C2 |
| METHOD FOR SIMULATING ENDOTHELIAL DYSFUNCTION AND PATHOLOGY OF INTERNAL ORGANS IN EXPERIMENT | 2019 |
|
RU2712102C1 |
| AGENT POSSESSING NEUROPROTECTIVE ACTION IN ISCHEMIC CEREBRAL CIRCULATION DISORDER | 2015 |
|
RU2586301C1 |
